483
Jiangsu Hengrui Pharmaceuticals Co., Ltd.FDA 483 - Jiangsu Hengrui Pharmaceuticals Co., Ltd. - April 04, 2025
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
Record Details
An FDA inspection of Jiangsu Hengrui Pharmaceuticals Co., Ltd. in Lianyungang, China, revealed a significant quality system deficiency. The firm failed to establish adequate written procedures for annual evaluations and its annual product review was insufficient in trending to decrease visible particulates in sterile injection products released to the United States.
Open in Dashboard
ID · eb46bf2d-a78b-4bac-87f4-f509775ee966